Verseon Corporation is a pharmaceutical company. The Company's platform models interactions between a protein and a drug molecule with precision sufficient for designing drug candidates. The Company operates through the pharmaceutical research segment. The Company uses its drug discovery technology to develop a portfolio of programs targeting disease areas consisting of anti-coagulation, diabetic macular edema (DMA) and oncology. The Company's platform generates a range of drug-like, synthesizable compounds, which are then computationally tested against a disease-causing protein to identify the binders, the drug candidates that could potentially treat the disease. These computationally designed candidates are synthesized and sent through a series of disease specific in vitro and in vivo tests to identify the candidates for clinical testing in humans.